1. Outcomes with catheter-directed thrombolysis vs. catheter-directed embolectomy among patients with high-risk pulmonary embolism: a nationwide analysis.
- Author
-
Sedhom R, Elbadawi A, Megaly M, Athar A, Bharadwaj AS, Prasad V, Cameron SJ, Weinberg I, Mamas MA, Messerli AW, Jaber W, and Elgendy IY
- Subjects
- Humans, Catheters, Embolectomy, Hemorrhage chemically induced, Intracranial Hemorrhages etiology, Retrospective Studies, Thrombolytic Therapy methods, Treatment Outcome, Fibrinolytic Agents therapeutic use, Pulmonary Embolism surgery, Pulmonary Embolism drug therapy
- Abstract
Aims: To examine the shot-term outcomes with catheter-directed thrombolysis (CDT) vs. catheter-directed embolectomy (CDE) for high-risk pulmonary embolism (PE)., Methods and Results: The Nationwide Readmissions Database was utilized to identify hospitalizations with high-risk PE undergoing CDE or CDT from 2016 to 2019. The main outcome was all-cause in-hospital mortality. Propensity score matching was used to compare the outcomes in both groups. Among 3216 high-risk PE hospitalizations undergoing catheter-directed interventions, 868 (27%) received CDE, 1864 (58%) received CDT, and 484 (15%) received both procedures. In the unadjusted analysis, the rate of all-cause in-hospital mortality was not different between CDE and CDT (39.6% vs. 34.2%, P = 0.07). After propensity score matching, there was no difference in the incidence of in-hospital mortality [adjusted odds ratio (aOR): 1.28, 95% confidence interval (CI): 0.95, 1.72, P = 0.10], intracranial haemorrhage (ICH) (adjusted OR 1.57, 95% CI: 0.75, 3.29, P = 0.23), or non-ICH bleeding (aOR: 1.17, 95% CI: 0.85, 1.62, P = 0.33). There were no differences in the length of stay, cost, and 30-day unplanned readmissions between both groups., Conclusion: In this contemporary observational analysis of patients admitted with high-risk PE undergoing CDT or CDE, the rates of in-hospital mortality, ICH, and non-ICH bleeding events were not different., Competing Interests: Conflict of interest: I.W. is a consultant for Magneto Thrombectomy Solutions and PI for Penumbra, Inc. A.S.D. is a consultant and speaker for Abiomed; Cardiovascular Systems, Inc.; and Shockwave. A.W.M. is a consultant and speaker for Boston Scientific., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF